Change search
ReferencesLink to record
Permanent link

Direct link
Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF
Duesseldorf, Germany.
Duesseldorf, Germany.
Ulm, Germany.
Duesseldorf, Germany.
Show others and affiliations
2015 (English)In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 21, no 8, 1036-1044 p.Article in journal (Refereed) Published
Abstract [en]

Background: Natalizumab for multiple sclerosis (MS) increases the risk of progressive multifocal leukoencephalopathy (PML). Objective: We aimed to assess the effect of natalizumab on cellular composition and functional B cell parameters including patients with natalizumab-associated PML (n=37). Methods: Cellular composition by flow cytometry, levels of immunoglobulin (Ig)G/IgM by immunonephelometry, and oligoclonal bands by isoelectric focusing were studied in blood and cerebrospinal fluid. Results: In MS patients treated with natalizumab without PML (n=59) the proportion of CD19+ B cells was higher in blood, but lower in cerebrospinal fluid compared with MS patients not treated with natalizumab (n=17). The CD4/CD8-ratio in cerebrospinal fluid was lower, and IgG and IgM levels as well as the IgG index dropped in longitudinal samples during natalizumab therapy. Oligoclonal bands persisted, but the total amount of the intrathecally produced IgG fraction, and the polyclonal intrathecal IgG reactivity to measles, rubella, and zoster declined. At the time of diagnosis of PML patients with natalizumab-associated PML had low total IgG levels in blood and cerebrospinal fluid. Conclusions: Natalizumab impacts B and T cell distribution and exerts an inhibitory effect on surrogates of B cell function in periphery and in cerebrospinal fluid, potentially contributing to the increased risk of developing PML.

Place, publisher, year, edition, pages
Sage Publications, 2015. Vol. 21, no 8, 1036-1044 p.
Keyword [en]
Progressive multifocal leukoencephalopathy, JC virus, natalizumab, Tysabri, multiple sclerosis, sease-modifying therapies, immunosuppression
National Category
URN: urn:nbn:se:umu:diva-106787DOI: 10.1177/1352458514556296ISI: 000357738700011PubMedID: 25392339OAI: diva2:847571
Available from: 2015-08-20 Created: 2015-08-07 Last updated: 2015-08-20Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Svenningsson, Anders
By organisation
Clinical Neuroscience
In the same journal
Multiple Sclerosis

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 42 hits
ReferencesLink to record
Permanent link

Direct link